INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ --Eli Lilly and Company(NYSE: LLY) today announced the successful completion of its acquisition ofAtaiBeckley Inc.AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.
"Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief," saidCarole Ho,Lillyexecutive vice president and president,LillyNeuroscience. "AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing. It's the innovation this field needs, and we are committed to advancing them for patients who need more options."
The transaction was approved by AtaiBeckley shareholders at a special meeting held prior to closing.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.